Agilent Wins Two Scientists’ Choice Awards for Drug Discovery and Development Products
08 Februar 2024 - 2:00PM
Business Wire
Agilent Technologies Inc. (NYSE: A) announced today that it has
received two prestigious awards from SelectScience: Best New Drug
Discovery & Development Product of 2023 and Drug Discovery
& Development Webinar of the Year. These accolades highlight
Agilent’s commitment to innovation and excellence in drug discovery
and development.
The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 – Screening
Model was voted Best New Drug Discovery & Development Product
of 2023. The Agilent xCELLigence RTCA HT-BioTek BioSpa 8 integrates
the xCELLigence Real-Time Cell Analyzer (RTCA) HT instrument with
the BioTek BioSpa 8 automated incubator to expand the screening
throughput of your RTCA HT instrument to eight 384-well plates.
Label-free high-throughput xCELLigence Real-Time Cell Analysis is
ideal for screening viral-mediated cytopathic effects (CPE),
neutralizing antibodies, antibody-dependent cytotoxicity (ADCC),
and compound-mediated cytotoxicity.
The Drug Discovery & Development Webinar of the Year was
co-produced between Agilent and Dr. Agapitos Patakas, Chief
Scientific Officer, Antibody Analytics. The webinar, titled
‘Modeling the tumor microenvironment: An in vitro cell-based assay
for the characterization of multi-specific biologics and
immunotherapies’, highlights the benefit of utilizing the Agilent
xCELLigence Real-Time Cell Analyzer (RTCA) and Agilent NovoCyte
Flow Cytometer workflow solution to study T-cell exhaustion in
vitro.
“We are honored and delighted to receive these awards from
SelectScience and the scientific community,” said Todd Christian,
vice president and general manager of Agilent’s Cell Analysis
Division. “These awards reflect our commitment to providing
innovative and reliable solutions that empower our customers to
advance scientific discoveries and improve human health.”
The awards were presented at the 2024 SLAS International
Conference and Exhibition in Boston, Massachusetts, and recognize
the most innovative and effective technologies advancing drug
discovery and development in 2023.
The Scientists’ Choice Awards celebrate the laboratory products
and manufacturers that make a difference to the industry.
Scientists around the world choose the winners through online
voting and reviews.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.83 billion in fiscal 2023 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240208699467/en/
Catherine Kaye Agilent Technologies +44 (0)7775 410632
catherine.kaye@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
Von Mai 2023 bis Mai 2024